InvestorsObserver
×
News Home

Should Biotechnology Stock Arcutis Biotherapeutics Inc (ARQT) Be in Your Portfolio Monday?

Monday, September 26, 2022 02:20 PM | InvestorsObserver Analysts

Mentioned in this article

Should Biotechnology Stock Arcutis Biotherapeutics Inc (ARQT) Be in Your Portfolio Monday?

The 72 rating InvestorsObserver gives to Arcutis Biotherapeutics Inc (ARQT) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 88 percent of stocks in the Biotechnology industry, ARQT’s 72 overall rating means the stock scores better than 72 percent of all stocks.

Overall Score - 72
ARQT has an Overall Score of 72. Find out what this means to you and get the rest of the rankings on ARQT!

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 72 means the stock is more attractive than 72 percent of stocks.
This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Arcutis Biotherapeutics Inc Stock Today?

Arcutis Biotherapeutics Inc (ARQT) stock has gained 2.36% while the S&P 500 has fallen -0.78% as of 2:20 PM on Monday, Sep 26. ARQT has risen $0.43 from the previous closing price of $18.19 on volume of 401,056 shares. Over the past year the S&P 500 is down -17.53% while ARQT has fallen -19.78%. ARQT lost -$5.14 per share the over the last 12 months. Click Here to get the full Stock Report for Arcutis Biotherapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App